APS pregnancy losses are one of the most common treatable causes of recurrent pregnancy loss. Clinical trials have helped in delineating the dangers of prednisone use in pregnancy, and suggest that heparin and aspirin regimens are preferred. However, the clinical trials suffer from the lack of uniform definition of antiphospholipid antibody positivity, from inclusion of women with different past pregnancy histories, and from different timing of the onset of the therapeutic modalities tested. New research on the role of complement activation in murine APS pregnancy loss may change therapeutic options in the future.